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Summary
Background:  Prevention  of  arthroﬁbrosis  by  different  drugs  and  surgical  techniques  is  an  essen-
tial issue  in  modern  orthopedics.
Hypothesis:  Intra-articular  injection  of  bevacizumab  can  reduce  arthroﬁbrosis  on  the  rabbit’s
stiﬂe joint  model.
Materials  and  methods:  Arthroﬁbrosis  was  induced  in  the  right  stiﬂe  joint  of  thirty  male  New
Zealand white  rabbits  by  removing  the  cortical  bone  of  the  medial  femoral  condyle  under
general anesthesia.  The  rabbits  were  randomly  divided  into  three  equal  groups.  The  control
group received  intra-articular  injection  of  saline;  the  one-injection  group  received  a  single
dose of  bevacizumab  (2.5  mg/kg),  and  the  two-injection  group  received  two  intra-articular
injections;  the  operation  day  and  14  days  later.  Forty-ﬁve  days  after  surgery,  animals  were
sacriﬁced.  The  severity  of  ﬁbrosis  was  assessed  based  on  the  range  of  motion  of  the  joint,  a
macroscopic  adhesion  score,  and  histopathologic  variables  such  as  the  number  of  ﬁbroblasts  and
genous  matrix  deposition,  synovial  hyperplasia,  granulation  tissueof inﬂammatory  cells,  colla
formation,  vascular  proliferation,  and  presence  of  giant  cells.
 This study was carried out in: Research Center for Bone and Joint Diseases, Chamran Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran; Stem Cell and Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
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Results:  Although  no  statistically  signiﬁcant  differences  were  found  between  the  range  of
motion (P  =  0.222)  and  the  macroscopic  evaluation  (P  =  0.067)  of  the  control  group  and  the
one-injection  group,  all  microscopic  variables  regarding  the  prevention  of  arthroﬁbrosis  were
signiﬁcantly  superior  in  the  one-injection  group  except  granulation  tissue  (P  =  0.347).  Com-
pared to  the  one-injection  group,  the  two-injection  group  had  better  results  not  only  in  terms
of macroscopic  evaluation  (P  =  0.001  for  range  of  motion  and  0.012  for  visual  adhesion  score)
but also  in  most  of  the  histopathologic  variables  especially  the  number  of  ﬁbroblasts  (P  =  0.002),
vascularity  (P  =  0.028)  and  collagenous  matrix  deposition  (P  =  0.039).
Conclusion:  A  single  intra-articular  injection  of  bevacizumab  was  effective  for  prevention  of
microscopically  detected  arthroﬁbrosis  in  the  rabbit.  Compared  to  single  injection,  two  injec-
tions of  bevacizumab  improved  the  clinical  outcome.
Level  of  evidence:  Level  II.
© 2012  Published  by  Elsevier  Masson  SAS.
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rthroﬁbrosis,  deﬁned  as  abnormal  ﬁbrous  tissue  hyperpla-
ia  within  and  around  a  joint,  is  one  of  the  most  signiﬁcant
omplications  after  intra-articular  injuries,  surgeries,  infec-
ion,  and  joint  arthroplasties  [1—3]. The  most  disabling
linical  ﬁndings  are  persistent  loss  of  joint  motion,  pain,
nd  muscle  weakness  [4].  Intra-articular  adhesions  in  the
nee  joint  are  particularly  disabling.  Arthroﬁbrosis  can  lead
o  progressive  osteoarthritis  by  provoking  drastic  changes  in
nee  kinematics  [2,5].
Prevention  of  arthroﬁbrosis  is  the  best  strategy  [4].  Sev-
ral  surgical  approaches  [4,6]  and  agents  such  as  botulinum
oxin  [7],  hyaluronan  [8],  chitosan  [9],  proteoglycan  decorin
10], anti-inﬂammatory  drugs  [11], mitomycin  C  [12], and
arrier  effect  of  hyaluronic  and  amniotic  membrane  [13]
ave  been  suggested  to  reduce  arthroﬁbrosis.  The  efﬁcacy
f  other  drugs  such  as  enoxaparin  was  not  proven  [14].
The  physiological  mechanism  of  intra-articular  ﬁbrosis
till  remains  unclear;  however,  inﬂammatory  process  and
mmune  response  play  a  crucial  role  [2,3]. Recently,  control
f  cytokines  and  inﬂammatory  factors  has  been  investigated
s  possible  means  to  reduce  arthroﬁbrosis  [15,16].  Vascular
ndothelial  growth  factor  (VEGF),  the  most  potent  mediator
f  vascular  regulation  [17], has  multiple  effects  on  adhe-
ion  formation.  Apart  from  angiogenesis,  VEGF  facilitates
essel  permeability,  inﬂammatory  cells  migration,  deposi-
ion  of  ﬁbrinous  exudates,  and  subsequent  formation  of
he  extracellular  matrix  with  collagen  deposition  [2,18].
oreover,  it  has  been  shown  that  VEGF  is  released  by  ﬁbro-
lasts  and  monocytes  in  the  tumor  stromal  compartments
19].  Expression  of  VEGF  in  peritoneal  and  pelvic  adhesions
20—23],  proliferative  diabetic  retinopathy  [24], progres-
ive  idiopathic  pulmonary  ﬁbrosis  [25], rheumatoid  arthritis,
soriasis,  and  arthrosclerosis  [26]  was  shown.
Bevacizumab  (Avastin)  is  a  recombinant  humanized
onoclonal  lg  G1  antibody  targeting  VEGF.  It  could  dis-
upt  ﬁbroblast  proliferation,  inhibit  collagen  gel  contraction
bility,  and  induce  ﬁbroblast  death  at  high  concentrations
n  in  vitro  model  of  wound  healing  in  primary  human
enon’s  capsule  [27]. Also,  the  expression  of  transforming
rowth  factor  2 (TGF-2),  major  ﬁbrogenic  factor,  was
uppressed  by  bevacizumab  in  alkali-burned  mouse  cornea
28]. Moreover,  bevacizumab  was  signiﬁcantly  able  to  delay
w
ghe  development  of  arthritis  in  mice  and  prevent  intra-
eritoneal  adhesions  [18,29].
The  present  randomized  experimental  trial  in  rabbits  was
esigned  to  assess  the  efﬁcacy  of  intra-articular  injection  of
evacizumab  in  reducing  arthroﬁbrosis  and  tested  the  effect
f  two  injections  in  comparison  to  a  single  injection.  We
ypothesized  that  intra-articular  injections  of  bevacizumab
ould  reduce  arthroﬁbrosis  in  the  rabbit’s  stiﬂe  joint  model,
nd  that  repeating  injection  would  optimize  its  effect.
aterials and methods
nimals
he  experiment  protocol  was  approved  by  Ethics  Commit-
ee  of  Shiraz  University  of  Medical  Sciences.  The  study  was
onducted  on  thirty  mature  male  New  Zealand  white  rabbits
eighing  3.2  kg  (2.7—4.2  kg).  They  were  kept  under  standard
aboratory  conditions  (temperature  20 ◦C—22 ◦C,  relative
umidity,  14  hours  light  and  10  hours  dark)  in  60  ×  60  ×  60  cm
ages  under  speciﬁed  pathogen-free  conditions  with  free
ccess  to  water  and  food  at  Laboratory  Animal  Unit.
urgery
nesthesia  was  induced  by  intramuscular  injection  of
0  mg/kg  ketamine  (Ketalar,  Parke  Davis)  and  8  mg/kg
ylazine  (Rompun,  Bayer  AC,  Leverkusen,  Germany).  A  pre-
perative  dose  of  intramuscular  cefazolin  sodium  (50  mg/kg)
as  injected  for  infection  prophylaxis.  All  surgical  proce-
ures  were  performed  under  aseptic  condition  by  a  single
urgeon.  Induction  of  arthroﬁbrosis  was  performed  as  previ-
usly  described  in  the  literature  [16,30].  Arthrotomy  was
erformed  through  a medial  parapatellar  approach.  The
edial  gutter  of  the  femoral  condyle  was  exposed.  Using  a
emplate  marking  a  10  ×  5  mm  surface,  the  cortical  bone  was
emoved  by  a  dental  burr  at  a  depth  of  3  mm,  thus  exposing
he  cancellous  bone.  After  irrigation,  capsule  and  skin  were
utured  by  nylon.  Following  surgery,  the  joint  was  ﬁxed  in
ull  ﬂexion  by  a trans-articular  1.6  mm  diameter  Kirschner
ire  for  45  days.
The  animals  were  randomly  assigned  to  one  of  three
roups  of  10  rabbits.  Animals  of  the  one-injection  and
Bevacizumab  effect  on  arthroﬁbrosis  
Table  1  Modiﬁed  macroscopic  adhesion  score  for  evaluat-
ing arthroﬁbrosis.
Description  Score
No  adhesion  0
Weak, mild  adhesions  eliminated  by
minimal  manual  traction
1
Moderate  adhesions  eliminated  by
usual  manual  traction
2
Dense  adhesions  eliminated  by  knife 3
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1.2  in  the  one-injection  group  vs.  0.2  in  the  two-injection
group  (P  =  0.012).  The  mean  range  of  motion  in  the  two-the  two-injection  groups  were  given  2.5  mg/kg  [18]  beva-
cizumab  (Avastin.  Roche  100  mg/4  mL,  Basel,  Switzerland)
diluted  with  0.9%  normal  saline  to  the  extent  of  0.8  mL
volume.  Two  weeks  later,  under  local  anesthesia,  the  sec-
ond  dose  of  intra-articular  bevacizumab  (2.5  mg/kg)  was
injected  in  the  stiﬂe  joint  of  the  two-injection  group  rabbits.
An  identical  volume  of  sterile  normal  saline  was  injected  in
the  control  group.
After  the  procedure,  intramuscular  injection  of
buprenorphine  0.01  mg/kg  three  times  daily  [31]  and
acetaminophen  (2  mg/kg)  dissolved  in  100  mL  drinking
water  was  prescribed  for  5  days  as  analgesics.  Moreover,
three  doses  of  cefazolin  were  injected  intramuscularly.
Forty-ﬁve  days  after  surgery,  the  rabbits  were  sacriﬁced
with  a  high  dose  (200  mg/kg)  of  pentothal.
Macroscopic  evaluation
Trans-articular  Kirschner  wire  was  gently  removed  after
sacriﬁcing  the  animal  and  the  range  of  joint  motion  was
evaluated  with  an  orthopedic  goniometer  by  one  of  the  co-
author  who  was  blinded  to  group  allocation.  Then,  the  joint
was  opened  using  a  surgical  knife.  The  macroscopic  evalua-
tion  was  done  using  a  modiﬁed  visual  scoring  system  (Table  1)
as  described  by  Rothkopf  et  al.  [7,16,30,32].
Microscopic  evaluation
The  stiﬂe  joints  were  excised  while  preserving  all  connective
tissues.  The  samples  were  ﬁxed  in  10%  neutral  buffered  for-
malin.  The  tissue  samples  were  embedded  in  parafﬁn  blocks.
Sections  for  histopathological  evaluation  were  cut  in  6  m
transverse  sections  perpendicular  to  the  femoral  axis  and
stained  according  to  standard  laboratory  procedures  with
hematoxylin-eosin  (H&E).  Two  expert  pathologists  blinded  to
the  injection  protocol  examined  the  pathologic  slides.  The
number  of  ﬁbroblasts  in  ×400  magniﬁcation  of  the  micro-
scope  together  with  inﬂammatory  cells,  collagenous  matrix
deposition,  synovial  hyperplasia,  granulation  tissue  forma-
tion,  vascular  proliferation,  and  presence  of  giant  cells  were
investigated  and  scored  0,  1,  2,  and  3  for  absent,  mild,  mod-
erate,  and  severe  states  of  these  variables  in  each  tissue
section,  respectively  [7,33,34].
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tatistical  analysis
nalysis  was  done  using  SPSS,  version  18.0  for  windows  (SPSS
nc.  Chicago,  IL,  USA).  Continuous  variables  such  as  range  of
oint  motion  and  number  of  ﬁbroblasts  were  compared  using
tudent’s  t  test.  Chi2 test  or  Fisher’s  exact  test  were  used
or  nonparametric  values  including  microscopic  variables
nd  macroscopic  visual  scores.  Analysis  was  done  between
he  control  group  and  the  one-injection  group  and  between
he  one-injection  group  and  the  two-injection  group  respec-
ively.  P  value  less  than  0.05  was  considered  as  signiﬁcant.
esults
f  the  30  rabbits,  two  died  without  any  speciﬁc  cause  during
he  survey  (one  from  the  control  group  and  the  other  from
he  one-injection  group).  We  excluded  a  rabbit  from  the
wo-injection  group  because  of  a  septic  arthritis.  Finally,
here  were  27  rabbits  (nine  rabbits  in  each  group).  There
as  a  skin  necrosis  exposing  the  patellar  tendon  in  a  rabbit
f  the  two-injection  group,  but  the  joint  remained  proof  and
overed  by  the  retinaculum.  Interestingly,  this  sample  had  a
acroscopic  adhesion  score  of  zero.  Loosening  of  Kirschner
ires  occurred  in  17  rabbits  without  ﬁxation  loss.  Mean  and
tandard  deviation  of  different  histological  and  macroscopic
ariable  scores  in  each  group  are  shown  in  Table  2.
omparison  of  the  control  group  and  the
ne-injection  group
o  statistically  signiﬁcant  difference  was  found  between  the
wo  groups  in  terms  of  range  of  joint  motions  and  macro-
copic  adhesion  score.  The  mean  range  of  motion  in  the
ontrol  group  and  the  one-injection  group  were  58.3  and
5.5◦,  respectively  (P  =  0.222).  The  mean  macroscopic  adhe-
ion  score  was  2.2  in  the  control  group  and  1.2  in  the
ne-injection  group  (P  =  0.067).
There  were  statistically  signiﬁcant  differences  between
he  microscopic  aspects  of  the  two  groups,  except
ranulation  tissue  (P  =  0.347).  The  cellularity  including
nﬂammatory  cells  inﬁltration  and  ﬁbroblast  numbers  was
igher  in  the  control  group  (P  <  0.05).  The  number  of  ﬁbro-
lasts  in  the  microscopic  high  power  ﬁeld  was  higher  in
he  control  group  (mean  =  152.7  in  the  control  group  vs.
01.1  in  the  one-injection  group  with  P  =  0.003).  Also,
iant  cell  formation  was  more  prevalent  in  the  control
roup  (P  =  0.015).  The  vascular  density  was  less  in  the
ne-injection  group  (P  =  0.036)  and  also  collagen  deposition
P  =  0.037)  (Figs.  1  and  2).
omparison  of  the  one-injection  group  and  the
wo-injection group
he  macroscopic  criteria  of  these  two  groups  were  statisti-
ally  different.  The  mean  macroscopic  adhesion  score  wasnjection  group  was  97.7◦ vs.  65.5◦ in  the  one-injection
roup  (P  =  0.001).
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Table  2  Mean  and  standard  deviation  of  macroscopic  and  histopathologic  variables  in  different  groups.
Group:  mean  (SD)  Range  of
motion
(Degrees)
Macroscopic
adhesion  score
Cellularity  Number  of
ﬁbroblasts
Control  58.3  (10.6)  2.2  (.6)  2.6  (.5)  152.7  (37.8)
One-injection  65.5  (13.3)  1.2  (.6)  1.5  (.5)  101.1  (23.1)
Two-injections  97.7  (18.0)  .2  (.4)  1.3  (.7)  60.0  (22.9)
Group: mean  (SD) Collagen
deposition
Granulation
tissue
Vascular
proliferation
Inﬂammatory
cells
Giant  cells  Synovial
hyperplasia
Control  2.6  (.5)  2.4  (.7)  2.5  (.5)  2.4  (.5)  1.7  (.4)  2.5  (.5)
One-injection  1.8  (.6)  2.0  (.7)  1.6  (.7)  1.7  (.4)  1.1  (.3)  1.4  (.5)
Two-injections 1.0  (.5)  1.1  (.6)  .5  (.5)  1.1  (.3)  .5  (.7)  .5  (.7)
SD: standard deviation.
Statistically  signiﬁcant  differences  were  found  in  micro-
scopic  variables  except  granulation  tissue  (P  =  0.099).  The
number  of  ﬁbroblasts  observed  in  the  high  power  ﬁeld  of
the  microscope  was  higher  in  the  one-injection  group  (101.1
vs.  60.0  in  the  two-injection  group,  P  =  0.002).  The  number
of  inﬂammatory  cells  was  signiﬁcantly  lower  in  the  two-
injection  group  (P  =  0.015).  Also,  the  giant  cell  formation
and  synovial  hyperplasia  were  higher  in  the  one-injection
group  (P  =  0.026  and  P  =  0.026,  respectively).  The  vascular
density  was  lower  in  the  two-injection  group  (P  =  0.028)  and
also  collagen  deposition  (P  =  0.039)  (Figs.  2  and  3).
Discussion
Arthroﬁbrosis  provoked  by  intra-articular  surgery  or  trauma
is  a  serious  problem.  Its  pathogenesis  involves  inﬂammatory
and  immune  responses.  Inhibition  of  speciﬁc  cytokines  and
growth  factors  activities  were  shown  to  prevent  adherence
formation  by  neutralizing  the  ﬁbroblast  growth  factor-2  as
described  by  Fukui  et  al.  [15]. In  another  rabbit  model  [16],
Figure  1  Inﬂammatory  cell  inﬁltration,  ﬁbroblasts,  (green
arrow) and  giant  cells  (yellow  arrow)  with  more  collagenous
matrix deposition  (blue  arrow)  and  blood  vessels  (black  arrow)
in the  control  group  (H&E  ×  200).
it  was  shown  that  adhesions  were  prevented  by  continu-
ously  injecting  a  blocking  antibody  of  TGF-, a  growth  factor
inducing  the  differentiation  of  ﬁbroblasts  from  peripheral
blood  mononuclear  cells  [35,36]. Blocking  VEGF,  which  is  one
of  the  most  active  mediators  of  angiogenesis  and  vascular
permeability  [17], was  thought  to  have  the  same  effect.  In
fact,  neutralizing  VEGF  using  bevacizumab  over  a  short  time
interval  (1  to  2  weeks)  was  shown  to  limit  extra-osseous
adherence  formation  [37,38].  Although  a  single  injection
may  have  some  histological  effects,  Chung  et  al.  [39]  rec-
ommended  repeated  injections  of  intravitreal  bevacizumab
in  patients  with  proliferative  diabetic  retinopathy,  so  as  to
optimize  its  effect.
Our  study  showed  that  intra-articular  injections  of  beva-
cizumab  reduced  joint  ﬁbrosis  in  the  rabbit.  The  number
of  rabbits  in  each  group  was  small,  however  the  results
reached  signiﬁcance.  Second,  the  stiﬂe  joints  were  ﬁxed
only  by  trans-articular  Kirschner  wire  without  casting,  thus
explaining  the  high  rate  of  wire  loosening,  which  may  have
slowed  down  the  process  of  ﬁbrosis  formation.  Despite  these
limitations,  histopathological  observations  supported  the
Figure  2  The  cellularity  including  ﬁbroblasts  (green  arrow),
collagenous  material  (blue  arrow),  and  blood  vessels  (black
arrow) are  greater  in  the  one-injection  group  in  comparison  to
the two-injection  group  (H&E  ×  200).
Bevacizumab  effect  on  arthroﬁbrosis  
Figure  3  Less  cellularity  and  less  collagenous  material  depo-
sition  in  the  two-injection  group  (H&E  × 200).  Fibroblasts  are
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initial  hypothesis  and  conﬁrmed  the  effect  of  bevacizumab.
Because  the  adhesion  maturation  process  could  be  affected
by  the  remaining  circulating  bevacizumab  up  to  6  weeks
[18],  we  reinjected  bevacizumab  2  weeks  after  the  ﬁrst
injection  (i.e.  at  the  end  of  its  half-life  [40]) to  increase
its  activity  and  thus  obtained  improved  clinical  outcome.
Skin  necrosis,  which  was  seen  in  one  rabbit  in  the  two-
injection  group,  was  reported  as  a  serious  side  effect  of
bevacizumab  due  to  its  selective  therapeutic  effect  target-
ing  VEGF  [41,42].  However,  a  suboptimal  skin  suture  was
incriminated  in  this  particular  case  because  the  underlying
tissues  had  already  healed  and  the  joint  was  not  exposed.
Therefore  it  seems  reasonable  to  recommend  two  successive
injections.
In  conclusion,  two  intra-articular  injections  of  beva-
cizumab  diminished  ﬁbrosis  formation  in  the  rabbit  as
conﬁrmed  by  histological  and  also  clinical  ﬁndings.  Although
further  investigations  should  be  ﬁrst  undertaken  in  big  ani-
mals,  it  could  be  ultimately  planned  to  apply  the  same
protocol  in  clinical  practice  and  hoped  to  obtain  the  same
effects  in  human  orthopaedic  surgery.
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